RAKOVINA
THERAPEUTICS INC.

ADVANCING DRUG DISCOVERY WITH THE PRECISION & POWER OF AI

TSX.V: RKV FSE: 7JO0

Investor Presentation | Q2 2026



Forward-Looking Statements

This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company; the Company's commitment to advancing new cancer therapies; the ability of the Company to extract value from the Deep Docking AI platform and the Enki AI platform; the Company's ability to execute on its business plans while maintaining high standards of research; and the Company's ability to generate shareholder value. Forward-looking events and circumstances discussed in this presentation may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at www.sedarplus.ca.

Investment Highlights

Three drug programs. First-in-class targets. Access to Proven AI Platforms.
One of the most compelling entry points in early-stage oncology.

First-in-Class Science, World-Class Team

Currently developing the first **dual ATR/mTOR inhibitor**. The team brings **100+ combined years of experience** across drug discovery, clinical development, and capital markets; and **includes AstraZeneca's former DDR program lead as a key scientific advisor.**

Proven AI Platforms

The **deep docking** platform screened **1.3B compounds in 3.5 weeks**[11-12] during COVID-19 and produced a drug licensed to Roche for **$140M+**[15] — one of the largest pharma IP deals by a Canadian university. The **generative AI** platform is validated through major pharma partnerships.

Validated Drug Class — $25B in Big Pharma Investment[7-10]

DNA Damage Response is one of oncology's most proven drug classes. Rakovina is pursuing the same targets with a **differentiated and more precise approach.**

Asymmetric Risk/Reward

Comparable preclinical and discovery stage programs have been licensed for $1.2B–$1.5B[7-10]. Comparable companies have raised institutional funding at premium valuations.



OUR SOLUTION

AI-Powered Drug Discovery

Rakovina combines two proven AI platforms with state-of-the-art lab infrastructure to discover next-generation cancer therapies — faster, more precisely, and at a fraction of the cost.

The AI Advantage

Traditional: thousands of compounds, 4–6 years. **AI-driven: billions of compounds, months** with improved safety profiles.

AI Platforms

deep docking platform + generative AI platform + EnsaliX (NanoPalm)

From AI to Lab

In-house validation of compounds at UBC & Vancouver Prostate Centre. AI outputs refined with real experimental data.

DNA Damage Response (DDR) is our entry point

The same AI platforms that power our DDR pipeline are designed to evaluate any biological target — **giving Rakovina a platform capability extending beyond a single drug class.**

The result: A faster, lower-cost, lower-risk path from scientific insight to cancer drug candidate. All candidates owned by Rakovina.

MARKET CONTEXT

AI Drug Discovery Companies with Wet Lab Capabilities — Attracting Hundreds of Millions in Institutional Capital and Billion-Dollar Pharma Deals

Rakovina combines AI-driven drug discovery with in-house wet lab validation — the same model that has attracted significant institutional capital and major pharma partnerships across this peer group.

Company	Rakovina (RKV)	Iambic AI	Insilico Medicine	Relay Therapeutics	Recursion
AI + Wet Lab	YES	YES	YES	YES	YES
Own Drug Pipeline	Yes - 3 programs	Yes — HER2, KIF18A, CDK2/4	Yes — 30+ programs	Yes — PI3Kα, FGFR2	Yes — oncology + rare disease
Development Stage	Discovery / Lead Opt.	Phase 1 Clinical	Phase 2 (IPF); 10+ INDs	Phase 2 (breast cancer)	Phase 2; 10 clinical readouts
Capital Raised/ Valuation	CAD ~$3M Valuation	~$327M raised	~$500M+ raised	Public (NASDAQ: RLAY) ~$3B peak valuation	Public (NASDAQ: RXRX) ~$4B peak valuation
Key Pharma Validation	deep docking platform — Roche $140M+; Variational AI — Merck $349M	Takeda — up to $1.7B (2026); Jazz Pharmaceuticals collab	Sanofi — $1.2B; Lilly — $100M+; Merck (via platform)	Pfizer collaboration (Phase 2 combo trial)	Bayer — 40+ programs; Genentech collaboration

Every company in this peer group combines AI with in-house wet lab validation and their own drug pipeline — and has attracted $250M+ in capital or billion-dollar pharma deals. **Rakovina is building the same model.**

VALIDATION

Our AI Platforms Are Proven — Not Theoretical

The technologies behind our drug discovery engine has been tested in the real world, licensed to major pharma, and validated through global partnerships.

Real-World Proof

During COVID-19, UBC partnered with Nvidia and Dell to utilize the deep docking platform to seek out potential drug candidates. The platform screened **1.3 billion** compounds in **3.5 weeks**[11,12]. The results were published, giving scientists around the world access to the most promising structures for therapies.

Commercial Validation

The deep docking platform developed a drug licensed to **Roche for $140M+ USD**[15] — the largest pharma IP deal in Canadian university history at the time.

The generative AI platform is validated through big pharma partnerships.

Rakovina owns the rights to **all novel drug candidates** generated through collaborations — combining proven AI with a **fully integrated preclinical validation infrastructure.**

THE UNMET NEED

Millions of Cancer Patients Have Limited Treatment Options

Cancer is the second-leading cause of death in the US, with 2M+ new cases annually[5]. Treatment becomes much more difficult for patients whose cancer has spread to the brain.

The Scale of the Problem

The most common cancers frequently metastasize to the brain, where the blood-brain barrier blocks most therapeutics.

- **~55% of lung cancer** patients develop brain metastases[14]
- **~40% of breast cancer** patients develop brain metastases[14]

The Drug Development Gap

Traditional drug development is slow, expensive, and failing patients.

- **14+ years from discovery** to approval
- **Billions of dollars** in development costs

This is the problem Rakovina Therapeutics was built to solve.

SCIENCE FOUNDATION

DDR Is One of Oncology's Most Validated Drug Classes

DNA Damage Response (DDR) pathways are the cell's repair system. Drugs targeting DDR have become one of oncology's most commercially successful approaches.



How DDR Works

DDR pathways repair DNA damage; when they fail, mutations accumulate and drive cancer.



Selective Kill

Cancer cells rely on backup repair pathways. DDR drugs block these backups, causing selective cancer cell death.



AI-Specific Moat

30+ years of PARP inhibitor data = the richest training set for AI-driven DDR drug discovery.

$18B

DDR Market by 2030

Precedence Research

30+

Years of PARP Data

Robust AI training sets

BIG PHARMA VALIDATION

Over $25B Invested in DDR by the World's Largest Pharma Companies


Novartis (NOVN) / Artios Pharma
April 2021 — **$1.3B** ($20M upfront)
Drug Discovery stage at signing

Merck (MRK) / Hengrui
Oct 2023 — **$1.5B** ($169M upfront)
PARP inhibitor | Phase 1 at signing

Roche (ROP) / Repare Therapeutics (RPTX)
June 2022 — **$1.2B** ($125M upfront)
ATR inhibitor | preclinical at signing

Sanofi (SAN) / Remix Therapeutics
Dec 2021 — **$1.2B** ($55M upfront)
Drug discovery stage at signing

Rakovina is pursuing validated targets— **with a more precise approach (dual functioning and brain penetrant)**



Deal values sourced from company press releases at time of announcement. References can be found on slide 28, references 7-10.

MARKET OPPORTUNITY

An $18B Market Opportunity. Proven Drug Class

$18B

DDR Market by 2030

Annual market potential (Precedence Research)

$5.5B

ATR Inhibitor Market

Estimated market by 2033

$2.3B

PARP Revenue

Annual revenue from first-generation PARP inhibitors

$366B

Global Oncology by 2034

Projected from $179B in 2024 (CAGR 7.4%)

$245B+

US Cancer Costs by 2030

Projected from ~$200B in 2020

2M+

New Cases Annually

In the US alone

All market size projections are third-party estimates and subject to change. Market sizing references can be found in references 1-6 on Slide 28

DRUG DEVELOPMENT PORTFOLIO

Rakovina Pipeline Overview

DDR Pipeline	AI Platform	Indication	Discovery	Lead Opt.	Pre-clinical	Clinical
Dual ATR/mTOR (kt-5000AI)	Enki - generative AI	Solid tumors, PTEN-deficient, CNS metastases	● →			
Dual PARP/HDAC (kt-3000)	EnsaliX	PARP-resistant adult & childhood cancers	● →			
PARP (kt-2000AI)	deep docking	Breast, ovarian, prostate cancers	● →			

kt-5000AI

First-in-class dual ATR/mTOR inhibitor designed for CNS penetration

kt-3000

Dual PARP/HDAC inhibitor outperforming FDA-approved drugs in preclinical models — co-development with NanoPalm Ltd.

kt-2000AI

Brain-penetrant PARP-selective inhibitor benchmarked against competition

Note: AI-compressed timelines allows for discovery to lead optimization in **12–18 months** versus 4–6 years with traditional methods.

MARKET VALIDATION

First-in-Class DDR Targets — Built to Reach the Brain

The DDR space has attracted billions from the world's largest pharma companies. Rakovina targets the same mechanisms — with a differentiated approach.

Criteria	Rakovina (RKV)	AstraZeneca	Repare/Roche	Artios/Novartis	Big Pharma
Primary Target	ATR/mTOR + PARP + PARP/HDAC	PARP1	ATR inhibitor	DDR / ATR	PARP, ATR
CNS / BBB Penetration	**YES (2000 & 5000 series)**	Partial	No	No	Limited
Dual ATR/mTOR	**YES — First-in-class**	No	No	No	No
PTEN-Mutant Focus	**YES**	No	No	No	Limited
AI-Driven Discovery	**deep docking + Enki + EnsaliX**	Internal	Partial	Partial	Varies
Pharma Validation	Roche $140M+[15]	Internal	$1.2B deal[9]	$1.3B deal[10]	N/A

First-In-Class

First dual ATR/mTOR inhibitor in development worldwide.

No Approved Treatments

PTEN-mutant cancers affect 30–85% of patients — with zero FDA-approved targeted therapies.

Deep Value

Comparable programs licensed at $1.2B–$1.5B[7-10]. Rakovina trades at a fraction of this.

Billions invested in DDR by the world's largest pharma companies — but **no program in development crosses the blood-brain barrier. Rakovina's does.**

kt-5000AI

First-in-Class Dual ATR/mTOR Inhibitor Designed to Reach the Brain

Science Summary

AI: Generative AI

Indication: Solid tumors, PTEN-deficient, CNS metastases

- 138 molecules predicted; 43 synthesized; leads confirmed potent and selective
- CNS penetration and tolerability confirmed in vivo
- AACR 2026 data presentation April 2026
- SNO data presentation November 2025
- Expanded Variational AI collaboration for lead optimization, 2026

2026 Milestones

- In vivo model data at peer-reviewed meetings
- Lead-optimization results from expanded AI collaboration & Lead selection
- Ongoing partner discussions

Market Opportunity

$5.5B

ATR Market by 2033[2]

0

Dual ATR/mTOR Competitors

Cancer cells with PTEN loss are vulnerable to ATR inhibition, but mTOR activates as an escape pathway. Targeting ATR and mTOR simultaneously yields enhanced efficacy. **FIrst dual ATR/mTOR inhibitor in development.**

kt-5000AI

First-in-Class Dual ATR/mTOR Inhibitor Designed to Reach the Brain

PTEN is one of the most commonly mutated genes in human cancer. When PTEN is lost, cancer cells become uniquely vulnerable to ATR inhibition — but blocking ATR alone triggers mTOR as an escape route, allowing tumors to keep growing. Rakovina's kt-5000AI blocks both simultaneously. **No other company is developing this dual approach.**

Cancer Type	PTEN Loss[13]	CNS Metastases[14]	Unmet Need
Lung cancer	~35–55%	~55% NSCLC	High
Breast cancer	~30–40%	~40%	High
Prostate cancer	~25–50%	~8%	High
Colorectal cancer	~10–40%	~6%	High
Ovarian cancer	~30–50%	~5%	High
Endometrial carcinoma	~50%	1–2%	High
Glioblastoma	~80–85%	Primary brain	Critical

> **ZERO** dual ATR/mTOR inhibitors in development worldwide. **ZERO** FDA-approved targeted therapies for PTEN-mutant cancers.

kt-3000

Dual PARP/HDAC Inhibitor Outperforming Approved Drugs

Peer-reviewed publication in Clinical Cancer Research is a major credibility signal.

Science Summary

Indication: PARP-resistant adult and childhood cancers, including Ewing sarcoma

- Superior cytotoxicity vs. FDA-approved olaparib and vorinostat
- Published in *Clinical Cancer Research* (peer-reviewed)
- AACR Annual Meeting presentation, April 2026

Strategic JV & Next Steps

NanoPalm JV: Rakovina's AI drug discovery + NanoPalm's self-targeting pLNP delivery system. Rakovina retains IP rights. Non-dilutive funding.

2026 Milestones

- JV funding secured
- ADC partnership
- Nano-lipid formulation data at peer-reviewed meetings

Combined PARP/HDAC inhibition shows improved efficacy. kt-3283 inhibits Ewing sarcoma growth **superior to single-agent PARP or HDAC inhibitors — and superior to their combination.**

kt-2000AI

kt-2000AI: Brain-Penetrant PARP Inhibitor

First-generation PARP inhibitors achieved commercial success but are limited by side effects and cannot treat brain metastases.

AI: deep docking platform

Indication: Breast, ovarian, prostate cancers

- Billions of compounds screened via Deep Docking
- 389 compounds assessed against PARP
- Leads confirmed with PARP selectivity and drug-like properties
- SNO data presentation November 2025

Market Opportunity

$2.3B

Annual PARP Revenue[3]

Rakovina screened billions of compounds to identify leads with **improved PARP CNS exposure — benchmarked against competition**

MILESTONES

Three Programs. Proven Science. Real Results.

AI-discovered drug candidates have advanced from computational screening to preclinical validation with growing evidence of efficacy, selectivity, and brain penetration.

Q1 2026

ATR/mTOR First AI output from lead optimizer; in vitro testing initiated

PARP/HDAC: NanoPalm delivers first LNP formulation

Q2 2026

ATR/mTOR In vitro compound testing and refinement through iterative AI rounds

PARP/HDAC: In vivo ADME/efficacy testing of LNP formulations

PARP: Round of AI output; in vitro testing begins

Corporate: AI partner strengthening and SAB talent, AACR conference

Q3 2026

ATR/mTOR: In vivo ADME/efficacy; lead candidate selection advancing

PARP/HDAC: Continued in vivo studies

Corporate: Saudi JV finalized

Q4 2026

ATR/mTOR: Lead selected

PARP: Round of AI output; lead candidate selection advancing

Corporate: Secure institutional funding, conferences: SNO, AACR-NCI-EORTC, BIO Middle East

H1 2027

ATR/mTOR: GLP tox / IND-enabling studies

PARP/HDAC: GLP tox / IND-enabling studies

PARP: PARP program lead selection

Corporate: Strategic pharma partnerships developing

The foundation is built. The science is validated. **The next phase is acceleration.**

LEADERSHIP

Experienced Team. Track Record of Success

Deep expertise in drug discovery, preclinical/clinical development, capital markets, and pharma partnering.



Kim Oishi — CEO

25+ years capital markets; Founder Grand Rock Capital; public company director



Mads Daugaard, PhD — President & CSO

20+ years translational cancer/DDR research; Co-founder Artemis AI



Frank Holler — Director

Former CEO of Xenon Pharmaceuticals (NASDAQ) and ID Biomedical (sold to GSK)



David Kideckel, PhD, MBA — CFO

20+ years life sciences & capital markets; prior J&J, Alexion, ATB Cormark



John Langlands, PhD — COO

30+ years preclinical/clinical pharmaceutical development



Michelle Seltenrich — VP Operations

25 years biotech finance; former Zymeworks FP&A Director

Scientific Advisory Board

Globally respected advisors providing strategic insight and credibility to attract partners and investors.

Dennis Brown, PhD — Chair

35+ years cancer drug discovery; National Brain Tumor Society; Co-founded Matrix Pharma, ChemGenex, Kintara

Petra Hamerlik, PhD

Former Director, AstraZeneca — led DDR program. Chair Translational Neuro-Oncology, Univ. of Manchester

Artem Cherkasov, PhD

Developed Deep Docking; 80+ Patents; 200+ peer-reviewed publications

Leonard Post, PhD

Developed PARP inhibitor (Talazoparib) licensed to Pfizer; Former CSO BioMarin; former SVP R&D Onyx Pharmaceuticals

Corporate Summary

Exchange	TSX-Venture | Frankfurt
Symbol	RKV.V | 7JOO
Sector	Biotech/ Artificial Intelligence
Year High / Low	CAD $0.84 / $0.085
Shares Outstanding	24,413,627
Fully Diluted	41,004,454
Warrants	15,193,077
Market Cap	~CAD $3 million
Auditors	Davidson & Company LLP

Rakovina represents a **deep-value entry point** into a validated drug class where comparable programs have been licensed at **$1.2B–$1.5B** at preclinical and discovery stages.

Contact: ir@rakovinatherapeutics.com | rakovinatherapeutics.com Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5


Appendix



Mission Statement

> Rakovina Therapeutics is developing DNA Damage Response (DDR) cancer therapies. Access to two robust AI platforms speeds up discovery timelines, increases precision, and greatly reduces risk. State-of-the-art laboratories at UBC and the Vancouver Prostate Centre enable rapid preclinical validation. A proven executive team brings it all together.

AI Powered Drug Development



Traditional vs. AI-Driven

Traditional: Thousands of candidates → 4–6 years to select a lead → 14 years and billions of dollars total.

AI-Driven: Billions of candidates → 12–18 months to select a lead → Reduced time, cost, and risk → Strategic Big Pharma partnerships to accelerate clinical success.

kt-5000AI Poster Data — AACR April 2026

A novel brain-penetrant dual ATR-mTOR inhibitor for PTEN-deficient cancers

https://www.rakovinatherapeutics.com/wp-content/uploads/2026/04/AACR2026_ATR-mTOR-Poster-final_16April2026.pdf

- AI-driven drug discovery has the potential to streamline the identification of new best-in-class drug candidates for the treatment of many diseases, including cancer.
- Using the Enki™ generative AI platform, we have generated and synthesized a curated list of small-molecule drug candidates meeting a specific target-product-profile in silico, specifically, novel dual ATR and mTOR inhibitors which are brain penetrating.
- Dual ATR and mTOR inhibitors are effective at inhibiting cell viability of PTEN-deficient cancer cells and are well tolerated after a single dose in mice.
- Candidate inhibitors show varying levels of CNS penetrance, activity, and metabolic stability which is broadly consistent with AI predictions
- Compound D shows equal efficacy in vivo compared to ceralasertib with decreased weight loss and no signs of hematological toxicity.
- Further optimization of candidate inhibitors is ongoing.

Reference main deck Slide 13 for summary context.

kt-3283 LNP Poster Data — AACR April 2026

Development of a Lipid Nanoparticle Formulation of the Bifunctional PARP and HDAC Inhibitor Kt-3283

https://www.rakovinatherapeutics.com/wp-content/uploads/2026/04/AACR2026_kt-3283-LNP-Poster-final_16April2026.pdf

- kt-3283, a potent inhibitor of PARP and HDAC enzymes, can be encapsulated into a patterned lipid nanoparticle designed by the EnsaliX AI platform
- pLNP-kt-3283 is uniform in particle size and surface charge, with stable colloidal behavior
- pLNP-kt-3283 is formed through organized lipid assembly, with a hexadome structure
- Further development of pLNP-kt-3283 includes in vitro and in vivo characterization to confirm activity of pLNP-kt-3283 against PARP and HDAC enzymes, determine ADME properties and determine efficacy of pLNP-kt-3283 against in vivo tumor models

Reference main deck Slide 13 for summary context.

kt-5000AI Poster Data — SNO November 2025

https://www.rakovinatherapeutics.com/wp-content/uploads/2026/01/SNO2025_ATR-Poster-final_17Nov2025.pdf

Full drug discovery process diagram, ATR inhibition graphs, ADME profiling data, and PK profiling charts from the Society for Neuro-Oncology Annual Meeting poster presentation.

AI Design → Validation → Lead Selection

Complete pipeline visualization

Potent ATR/mTOR Inhibitor

Confirmed CNS penetration

In Vivo Tolerability

Demonstrated in preclinical models

Reference main deck Slide 11 for summary context.

kt-2000AI Poster Data — SNO November 2025

https://www.rakovinatherapeutics.com/wp-content/uploads/2026/01/SNO2025_2000AI-Poster-final_3Nov2025.pdf

Full compound summary, PARP1/PARP2 assay data, ADME profiling, and PK comparison vs. AZD9574 and olaparib from the Society for Neuro-Oncology Annual Meeting poster presentation.



Reference main deck Slide 12 for summary context.

REFERENCES

Sources & References

1. Precedence Research. "DNA Repair Drugs Market." precedenceresearch.com/dna-repair-drugs-market

2. Growth Market Reports. "ATR Kinase Inhibitor Market Research Report 2033." growthmarketreports.com/report/atr-kinase-inhibitor-market

3. Zion Market Research. "PARP Inhibitors Market Size, 2032." zionmarketresearch.com/report/parp-inhibitors-market

4. Nova One Advisor. "Oncology Drugs Market Size, 2034." novaoneadvisor.com/report/oncology-drugs-market

5. American Cancer Society. "Cancer Statistics, 2024." CA: A Cancer Journal for Clinicians. cancer.org/research/cancer-facts-statistics

6. National Cancer Institute. "Financial Burden of Cancer Care." progressreport.cancer.gov/after/economic_burden

7. Novartis / Artios Pharma. Collaboration agreement, Oct 2023. $1.5B ($169M upfront). novartis.com/news/media-releases

8. Merck / Hengrui. License agreement, Jun 2022. $1.2B ($125M upfront). merck.com/news

9. Roche / Repare Therapeutics. License agreement, Dec 2021. $1.2B ($55M upfront). roche.com/media/releases

10. Sanofi / Artios Pharma. Collaboration, Apr 2021. $1.3B ($20M upfront). sanofi.com/en/media-room/press-releases

11. Gentile F, et al. "Deep Docking." ACS Cent Sci. 2020;6(6):939-949. doi:10.1021/acscentsci.0c00229

12. UBC. "AI enables screening of billions of compounds for COVID-19." strategicplan.ubc.ca

13. Millis SZ, et al. PTEN prevalence data. J Natl Cancer Inst. 2019. pubmed.ncbi.nlm.nih.gov

14. Nayak L, et al. "Epidemiology of Brain Metastases." Curr Oncol Rep. 2012;14(1):48-54. pubmed.ncbi.nlm.nih.gov/22012633

15. UBC / Roche Pharma. Deep Docking compound licensed for $140M+ USD. news.ubc.ca

All market size projections are third-party estimates and subject to change. Deal values sourced from company press releases at time of announcement.